Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ-B3525 in Relapsed/Refractory CLL/SLL
NCT04808570Phase 2Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQ-B3525 in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jun 2021; status: terminated.
02
Drugs
TQ-B3525
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04808570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04808570.